Loading
Life sciences · Journal article
International Health Sciences Review · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The expanding efficacy of incretin-based pharmacotherapy has changed the comparison between metabolic and bariatric surgery and medical obesity treatment. This narrative critical review examines weight-loss durability, control of obesity-related complications, comparative evidence, and treatment selection using clinical trials, long-term surgical studies, contemporary guidelines, and comparative observational research identified through October 2026. Liraglutide, semaglutide, and tirzepatide produce different mean weight reductions, and outcomes also vary with dose, diabetes status, treatment exposure, and trial estimand. Continued pharmacotherapy can sustain substantial weight loss, whereas withdrawal trials demonstrate considerable regain. Surgery has longer follow-up and generally larger weight reductions in current comparative cohorts, but postoperative regain, diabetes relapse, nutritional deficiencies, and procedural complications remain clinically relevant. Semaglutide has demonstrated cardiovascular event reduction in a defined secondary-prevention population, while tirzepatide has disease-specific evidence in obesity-related heart failure and obstructive sleep apnea. These findings cannot be generalized indiscriminately across medications or equated with surgical remission outcomes. Direct contemporary comparisons remain predominantly observational; indirect randomized comparisons depend on uncertain comparability between trials. Treatment choice should therefore integrate required weight reduction, complication-specific evidence, operative risk, tolerability, access, and willingness to sustain follow-up. Sequential use of surgery and pharmacotherapy is a rational option supported by emerging evidence.